Y Peñate1, O Servitje2, S Machan3, R Fernández-de-Misa4, M T Estrach5, E Acebo6, J Mitxelena7, M D Ramón8, A Flórez9, M Blanes10, M Morillo11, S Medina12, J Bassas13, A Zayas14, P Espinosa15, A Pérez16, N Gónzalez-Romero17, J D Domínguez18, C Muniesa2, J López Robles3, A Combalia5, I Yanguas7, H Suh9, I Polo-Rodríguez12, I Bielsa13, A Mateu14, B Ferrer16, M A Descalzo19, I García-Doval20, P L Ortiz-Romero21. 1. Servicio de Dermatología, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas, España. Electronic address: ypenate@aedv.es. 2. Servicio de Dermatología, Hospital Universitari Bellvitge, L' Hospitalet de Llobregat, Barcelona, España. 3. Servicio de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España. 4. Servicio de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz Tenerife, España. 5. Servicio de Dermatología, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, España. 6. Servicio de Dermatología, Hospital de Cruces, Baracaldo, Vizcaya, España. 7. Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España. 8. Servicio de Dermatología, Hospital Clínico de Valencia, Valencia, España. 9. Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España. 10. Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España. 11. Servicio de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, España. 12. Servicio de Dermatología, Hospital Universitario Príncipe de Asturias., Alcalá de Henares, Madrid, España. 13. Servicio de Dermatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España. 14. Servicio de Dermatología, Hospital Universitario Dr. Peset, Valencia, España. 15. Servicio de Dermatología, Hospital Universitario Infanta Cristina, Parla, Madrid, España. 16. Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, España. 17. Servicio de Dermatología, Hospital Universitario de Basurto, Bilbao, Vizcaya, España. 18. Servicio de Dermatología, Hospital Universitario de Henares, Coslada, Madrid, España. 19. Unidad de Investigación. Fundación Piel Sana AEDV, Madrid, España. 20. Unidad de Investigación. Fundación Piel Sana AEDV, Madrid, España; Servicio de Dermatología, Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España. 21. Servicio de Dermatología, Hospital Universitario 12 de Octubre, Institute i+12, Medical School. Universidad Complutense, ONCOCIBER, Madrid, España.
Abstract
BACKGROUND AND OBJECTIVE: Primary cutaneous lymphomas are uncommon. This article describes the Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV) and reports on the results from the first year. PATIENTS AND METHODS: Disease registry for patients with primary cutaneous lymphoma. The participating hospitals prospectively recorded data on diagnosis, treatment, tests, and disease stage for all patients with primary cutaneous lymphoma. A descriptive analysis was performed. RESULTS: In December 2017, the registry contained data on 639 patients (60% male) from 16 university hospitals. The most common diagnoses, in order of frequency, were mycosis fungoides/Sézary syndrome (MF/SS) (348 cases, 55%), primary cutaneous B-cell lymphoma (CBCL) (184 cases, 29%), primary cutaneous CD30+ T-cell lymphoproliferative disorder (CD30+ CLPD) (70 cases, 11%), and other types of T-cell lymphoma (37 cases, 5%). In total, 105 (16.5%) of the cases recorded were incident cases. The most common diagnosis in the MF/SS group was classic MF (77.3%). Half of the patients with MF had stage IA disease when diagnosed, and the majority were either in partial remission (32.5%) or had stable disease (33.1%). The most widely used treatments were topical corticosteroids (90.8%) and phototherapy. The most common form of primary CBCL was marginal zone lymphoma (50%). Almost all of the patients had cutaneous involvement only and nearly half had stage T1a disease. Most (76.1%) were in complete remission. The main treatments were surgery (55.4%) and radiotherapy (41.9%). The most common diagnosis in patients with CD30+ CLPD was lymphomatoid papulosis (68.8%). Most of the patients (31.4%) had stage T3b disease and half were in complete remission. The most common treatments were topical corticosteroids (68.8%) and systemic chemotherapy (32.9%). CONCLUSION: The characteristics of patients with primary cutaneous lymphoma in Spain do not differ from those described in other series in the literature. The registry will facilitate clinical research by the AEDV's lymphoma group.
BACKGROUND AND OBJECTIVE:Primary cutaneous lymphomas are uncommon. This article describes the Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV) and reports on the results from the first year. PATIENTS AND METHODS: Disease registry for patients with primary cutaneous lymphoma. The participating hospitals prospectively recorded data on diagnosis, treatment, tests, and disease stage for all patients with primary cutaneous lymphoma. A descriptive analysis was performed. RESULTS: In December 2017, the registry contained data on 639 patients (60% male) from 16 university hospitals. The most common diagnoses, in order of frequency, were mycosis fungoides/Sézary syndrome (MF/SS) (348 cases, 55%), primary cutaneous B-cell lymphoma (CBCL) (184 cases, 29%), primary cutaneous CD30+ T-cell lymphoproliferative disorder (CD30+ CLPD) (70 cases, 11%), and other types of T-cell lymphoma (37 cases, 5%). In total, 105 (16.5%) of the cases recorded were incident cases. The most common diagnosis in the MF/SS group was classic MF (77.3%). Half of the patients with MF had stage IA disease when diagnosed, and the majority were either in partial remission (32.5%) or had stable disease (33.1%). The most widely used treatments were topical corticosteroids (90.8%) and phototherapy. The most common form of primary CBCL was marginal zone lymphoma (50%). Almost all of the patients had cutaneous involvement only and nearly half had stage T1a disease. Most (76.1%) were in complete remission. The main treatments were surgery (55.4%) and radiotherapy (41.9%). The most common diagnosis in patients with CD30+ CLPD was lymphomatoid papulosis (68.8%). Most of the patients (31.4%) had stage T3b disease and half were in complete remission. The most common treatments were topical corticosteroids (68.8%) and systemic chemotherapy (32.9%). CONCLUSION: The characteristics of patients with primary cutaneous lymphoma in Spain do not differ from those described in other series in the literature. The registry will facilitate clinical research by the AEDV's lymphoma group.
Authors: Pablo Luis Ortiz-Romero; Octavio Servitje; María Teresa Estrach; Rosa María Izu-Belloso; Ricardo Fernández-de-Misa; Fernando Gallardo; Noemí López-Martínez; Alejandro Pérez-Mitru Journal: Clinicoecon Outcomes Res Date: 2020-02-12